Cingulate (CING) Enterprise Value (2021 - 2026)
Cingulate's (CING) quarterly Enterprise Value came in at -$11.0 million in Q4 2025, up 10.3% YoY from -$9.9 million in Q4 2024, and down 79.56% on a QoQ basis from -$6.1 million in Q3 2025.
Cingulate (CING) Enterprise Value (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Enterprise Value data on file, last reported at -$11.0 million in Q4 2025.
- Quarterly Enterprise Value rose 10.3% year-over-year to -$11.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.0 million (up 10.3% YoY) and the FY2025 annual result came in at -$11.0 million, up 10.3% from the prior year.
- Enterprise Value slipped to -$11.0 million in Q4 2025, from -$6.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$52416.0 in Q4 2023 to a low of -$16.5 million in Q4 2021.
- A 5-year average of -$7.1 million and a median of -$7.8 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value soared 99.02% — and 2024, when it slumped 23196.93%.
- Tracing CING's Enterprise Value over 5 years: stood at -$16.5 million in 2021, then soared by 67.53% to -$5.4 million in 2022, then soared by 99.02% to -$52416.0 in 2023, then tumbled by 23196.93% to -$12.2 million in 2024, then grew by 10.3% to -$11.0 million in 2025.
- The last three Enterprise Value figures came in at -$11.0 million (Q4 2025), -$6.1 million (Q3 2025), and -$9.5 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | -28.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.40 Mn |
| Dec 31, 2025 | -10.95 Mn |
| Sep 30, 2025 | -6.10 Mn |
| Mar 31, 2025 | -9.50 Mn |
| Dec 31, 2024 | -12.21 Mn |
| Sep 30, 2024 | -10.04 Mn |
| Jun 30, 2024 | -380,928.00 |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | -52,416.00 |
| Sep 30, 2023 | -1.99 Mn |
| Jun 30, 2023 | -349,831.00 |
| Mar 31, 2023 | -1.74 Mn |
| Dec 31, 2022 | -5.36 Mn |
| Sep 30, 2022 | -9.80 Mn |
| Jun 30, 2022 | -15.71 Mn |
| Mar 31, 2022 | -12.62 Mn |
| Dec 31, 2021 | -16.49 Mn |